Zentalis Pharmaceuticals, Inc.
ZNTL
$3.86
-$0.17-4.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.23M | 9.14M | 3.77M | 10.78M | 8.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.39M | 37.86M | 34.46M | 33.73M | 36.06M |
| Operating Income | -44.39M | -37.86M | -34.46M | -33.73M | -36.06M |
| Income Before Tax | -42.15M | -35.23M | -34.77M | -26.69M | -26.87M |
| Income Tax Expenses | 138.00K | 120.00K | 442.00K | -- | -- |
| Earnings from Continuing Operations | -42.29M | -35.35M | -35.22M | -26.69M | -26.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.29M | -35.35M | -35.22M | -26.69M | -26.87M |
| EBIT | -44.39M | -37.86M | -34.46M | -33.73M | -36.06M |
| EBITDA | -44.24M | -37.70M | -34.30M | -33.57M | -35.90M |
| EPS Basic | -0.59 | -0.50 | -0.49 | -0.37 | -0.37 |
| Normalized Basic EPS | -0.37 | -0.31 | -0.30 | -0.23 | -0.24 |
| EPS Diluted | -0.59 | -0.50 | -0.49 | -0.37 | -0.37 |
| Normalized Diluted EPS | -0.37 | -0.31 | -0.30 | -0.23 | -0.24 |
| Average Basic Shares Outstanding | 71.33M | 70.26M | 71.66M | 72.14M | 71.99M |
| Average Diluted Shares Outstanding | 71.33M | 70.26M | 71.66M | 72.14M | 71.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |